Retrophin Logo.jpg
Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 16:01 ET | Retrophin, Inc.
Top-line results from pivotal Phase 3 FORT Study in PKAN expected in 3Q 2019 Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS...
Summit Master_rgb_png.png
Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
February 13, 2019 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection Trials Aim to Show...
Retrophin Logo.jpg
Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN
December 20, 2018 08:00 ET | Retrophin, Inc.
SAN DIEGO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced completion of patient enrollment in the pivotal Phase 3 FORT Study, which is evaluating the safety and...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease
December 20, 2018 07:00 ET | FibroGen, Inc
SAN FRANCISCO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today...
Retrophin Logo.jpg
Retrophin Reports Third Quarter 2018 Financial Results
November 01, 2018 16:01 ET | Retrophin, Inc.
Pivotal programs enrolling towards first data readout in 2019 Phase 2 study of CNSA-001 in PKU underway; top-line results expected in first half 2019 Completed offering of $276 million...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
October 16, 2018 08:00 ET | VBI Vaccines, Inc.
Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...
Adamas Pharmaceuticals Logo
Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease
October 04, 2018 09:00 ET | Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
erytech.jpg
ERYTECH annonce le recrutement des premiers patients dans son étude clinique de Phase 3 avec eryaspase pour le traitement en seconde ligne du cancer du pancréas
September 20, 2018 01:30 ET | Erytech Pharma S.A.
LYON, France et CAMBRIDGE, Mass., 20 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), société biopharmaceutique de stade clinique qui développe des thérapies...
erytech.jpg
ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
September 20, 2018 01:30 ET | Erytech Pharma S.A.
LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress
August 08, 2018 07:00 ET | uniQure Inc.
~ Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061 ~ First Patient Successfully Screened into Phase IIb Dose-Confirmation Trial of AMT-061 ~ Robert Gut, M.D., Ph.D.,...